The development of a liquid suspension form of delavirdine (Rescriptor) had disappointing results in one study. Most children rejected the liquid due to its bad taste and were switched to crushed or dissolved tablets, with anti-HIV properties similar to those seen in adult trials.1


  1. Willoughby R et al. Phase I / II evaluation of delavirdine in HIV-1-infected pediatric patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, abstract 1995, 1999
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.